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2) Abstract 37 
Background: The clinical metrics used to date to assess the progression risk of newly 38 
diagnosed prostate cancer patients only partly represent the true biological 39 
aggressiveness of the underlying disease. 40 
Objective: Validation of the prognostic biomarker PDE4D7 in predicting longitudinal 41 
biological outcomes in a historical surgery cohort to improve post-surgical risk 42 
stratification. 43 
Design, Patients and Methods: RNA was extracted from biopsy punches of resected 44 
tumors from 550 patients. PDE4D7 was quantified by one-step RT-qPCR. PDE4D7 45 
scores were calculated by normalization of PDE4D7 to reference genes. Multivariate 46 
analyses were adjusted for clinical prognostic variables. Outcomes tested were: PSA 47 
relapse, start of salvage treatment, progression to metastases, overall and prostate 48 
cancer specific mortality. The PDE4D7 score was combined with the clinical risk model 49 
CAPRA-S using multivariate regression modeling; the combined score was tested in 50 
post-treatment progression free survival prediction.  51 
Outcome measurements and statistical analysis: Correlations with outcomes were 52 
analysed using multivariate Cox regression and logistic regression statistics. 53 
Results and limitations: The PDE4D7 score was significantly associated with time to 54 
PSA failure after prostatectomy (HR 0.53; 95% CI 0.41-0.67 for each unit increase; 55 
p<0.0001). After adjustment for post-surgical prognostic variables the HR was 0.56 56 
(95% CI 0.43-0.73; p<0.0001). The PDE4D7 score remained significant after adjusting 57 
the multi-variate analysis for the CAPRA-S model categories (HR=0.54, 95% CI=0.42-58 
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0.69, p<0.0001). Combination of the PDE4D& score with the CAPRA-S demonstrated 59 
significant incremental value of 4-6% in 2-year (p=0.004) or 5-year (p=0.003) prediction 60 
of progression free survival after surgery. The combined model of PDE4D& and CAPRA-61 
S improves patient selection with very high risk of fast disease relapse after primary 62 
intervention.   63 
Conclusions: The PDE4D7 score has potential to provide independent risk information 64 
and to re-stratify patients with clinical intermediate to high-risk characteristics to a very 65 
low risk profile. 66 
 67 
Patient Summary: In this report we studied the potential of a novel biomarker to predict 68 
outcomes of a cohort of prostate cancer patients who underwent surgery more than 10 69 
years ago. We found that the gene called PDE4D7 added extra information to the 70 
available clinical data. We conclude that the measurement of this gene in tumor tissue 71 
may contribute to more effective treatment decisions.  72 
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3) Introduction 73 
Prostate cancer displays as a heterogeneous disease with varying potential to 74 
develop progressively to deadly forms of the disease. Of the estimated 417,000 annual 75 
new cases in Europe, around 92,000 will die from their disease.1  76 
Accurate risk stratification of prostate cancer patients is essential to identify men 77 
who benefit from adjuvant or multi-modality treatments while sparing those with low risk 78 
from the adverse effects of aggressive therapy. Various clinic metrics have been 79 
developed in the past to predict disease progression after primary treatments such as 80 
surgery or radiation therapy2. Typically, predictions are based on the combination of 81 
clinical variables that are available at the moment of clinical need. However, clinical risk 82 
descriptors are limited by the information content of their clinical input variables and do 83 
not necessarily describe effectively either the extent of the disease or its aggressiveness 84 
for all patients3,4,5. Thus, there is a need for better patient stratification in order to 85 
optimize disease management.  Additional molecular information representing the 86 
biology of the disease offers the potential to achieve this6. 87 
The cAMP signaling pathway is known to play an important role in both the 88 
development and progression of prostate cancer.7 While a family of adenylate cyclases 89 
is responsible for the synthesis of cAMP, cyclic nucleotide phosphodiesterases (PDEs) 90 
represent the only cellular mechanism for its destruction. PDEs provide both signal 91 
termination and, importantly, the compartmentalization of cAMP signaling within the 3D 92 
matrix of cells. This is achieved through the spatially discrete destruction of cAMP via 93 
sub-populations of distinct PDE isoforms sequestered by localized anchor 94 
proteins/signalosomes.8,9,10 Thus changes in the expression and/or activity of distinct 95 
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PDE isoforms can alter downstream signaling pathways during disease development 96 
and progression, providing potential targets for novel biomarkers and for targeted 97 
therapeutic intervention.  98 
In this study we demonstrate that PDE4D7 transcript levels correlate to the 99 
longitudinal outcome of prostate cancer after primary treatment. We further 100 
hypothesized that PDE4D7 independently adds to clinical risk stratification metrics like 101 
the Cancer of the Prostate Risk Assessment Postsurgical (CAPRA-S) score11, which 102 
may add value for clinical decision-making.  103 
  104 
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Patients and methods 105 
Patient cohorts and samples 106 
Two small adjacent biopsy punches (approx. 1x2 mm) of a representative resected area 107 
of the largest volume tumor of 550 patients operated on between 2000-2004 at Martini 108 
Klinik (Hamburg, Germany) were collected (Table 1) with local IRB approval. Patients 109 
with adjuvant hormone therapy were removed from the analysis. After data quality 110 
control based on pre-defined criteria 503 patient samples were eligible for statistical 111 
analysis (Supplementary Figures 1 & 2). For independent validation purpose we 112 
selected a prostate cancer data set published earlier.12 All men with primary prostate 113 
cancer with available post-surgical outcome data as well as PDE4D7 expression data 114 
based on exon array measurements were selected for the validation (n=130; Table 1). 115 
Laboratory methods 116 
RT-qPCR (quantitative real-time PCR) primers and probes are outlined in 117 
Supplementary Table 1. RNA extraction, RT-qPCR assay development and protocols 118 
are described in the Supplementary Materials. The limit of detection (LOD) for RT-qPCR 119 
Cq was determined and was used as a pre-defined quality threshold to discard samples 120 
from the statistical analysis (Supplementary Material). 121 
Data analysis and statistics 122 
Normalized PDE4D7 expression was calculated by subtracting the Cq of the respective 123 
PDE4D transcript from the averaged Cq of the reference genes13 and transformed to the 124 
PDE4D7 score (Supplementary Figure 3). The CAPRA-S risk score and corresponding 125 
low (1), intermediate (2), high-risk (3) categories were calculated as described earlier.11 126 
Uni- and multivariate Cox regression analysis and modeling was applied to correlate 127 
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BCR PFS to the PDE4D7 score in the study cohort (n=503) and the validation cohort 128 
(n=130). The PDE4D7 score was either used as a continuous or as a categorical 129 
variable. The multi-variate analyses were adjusted for post-surgical clinical variables.  130 
Logistic regression models to predict 2-year or 5-year BCR PFS were created 131 
using the CAPRA-S categories and the continuous PDE4D7 score as variables in the 132 
study cohort with complete 5-year follow-up (n=469 and 449, respectively). For statistical 133 
analysis the software packages MedCalc (MedCalc Software BVBA, Ostend, Belgium) 134 
or R (R Core Team (2016): A language environment for statistical computing. R 135 
Foundation for Statistical Computing, Vienna, Austria) were used. P values are two-136 
sided; statistical significance is based on alpha level ≤0.05.  137 
Analysis of GSE2103412: raw CEL files were downloaded from Gene Expression 138 
Omnibus. Data processing and RMA normalization were performed using the 139 
aroma.affymetrix R-package (Affymetrix Inc, CA, USA)14 and transcript expression was 140 
measured by averaging log2-transformed intensity values of the following isoform-141 
specific probe sets: PDE4D7 (2858406, 2858407 and 2858408). The normalized 142 
PDE4D7 expression values were transformed into a PDE4D7 score equivalent to the 143 
qPCR expression data.  144 
 145 
146 
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Results  147 
Correlation of PDE4D7 score to longitudinal clinical outcomes 148 
We set out to correlate the expression of the putative prostate cancer biomarker 149 
PDE4D7, which has recently been initially described by us13, to the longitudinal patient 150 
outcome of biochemical recurrence (BCR) after surgery. Although PSA relapse is 151 
regarded as a surrogate for more severe clinical outcomes like metastases or cancer 152 
specific death, it is nevertheless very often used as a trigger to start secondary 153 
treatments.  154 
Univariate and multi-variate Cox regression analysis demonstrated a significant 155 
correlation of the continuous PDE4D7 score to time to BCR (HR 0.53; 95% CI 0.41-0.67; 156 
p<0.0001, and HR 0.56; 95% CI 0.43-0.73, p=<0.0001, respectively; Table 2A; 157 
Supplementary Figure 4A). Adjusting the multi-variate Cox regression analysis for the 158 
prognostic CAPRA-S score resulted in a significant independent contribution to the 159 
prediction of post-surgical BCR for the continuous as well as the categorical PDE4D7 160 
score (Tables 2B and 2C; Supplementary Figures 4B and 4C).  161 
Next we investigated the hazard of biochemical progression across the 162 
continuous PDE4D7 score (Figure 1A). It is evident that patients with the highest 163 
PDE4D7 scores (>4) demonstrated virtually no risk of post-surgical progression. We 164 
observed a linear increase of the hazard between PDE4D7 scores 2-5 while a steep 165 
increase occurred when the PDE4D7 scores decreases below a value of 2. Although the 166 
number of men in this lowest PDE4D7 score category (1-2) is small (n=11) it seems that 167 
this group of men harbor a distinct form of prostate cancer as their risk clearly deviates 168 
from the observed linear increase of any PDE4D7 score >2. 169 
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Kaplan-Meier analysis revealed that the PDE4D7 score category (4-5) includes 170 
men with a <5% probability of 5-year BCR while the chance to experience this endpoint 171 
increased to >50% for patients in PDE4D7 score category (1-2) with all events occurring 172 
within 3.5 years after surgery (logrank p<0.0001; Figure 1B; Supplementary Table 4).  173 
When comparing the patient characteristics of the validation population to the 174 
study cohort (Table 1) we noticed a similar distribution of clinical risks for the low (41.9% 175 
vs. 44.6%; p=0.73) and intermediate favorable risk groups (25.4% vs. 24.6%; p=0.91) in 176 
both cohorts while there is a non-significant trend towards less unfavorable intermediate 177 
risk (16.2% vs. 23.9%; p=0.16) but more high risk cases (8.7% vs. 14.6%; p=0.08) in the 178 
study vs. the validation cohort (Table 1). Kaplan Meier survival analysis to correlate the 179 
four PDE4D7 score categories with BCR PFS showed very similar results as found in 180 
the study cohort  (logrank p=0.036) (Figure 1C; Supplementary Table 5). 181 
Testing of other clinical endpoints othen than BCR demonstrated equivalent 182 
association of PDE4D7 in the Cox regression analysis (Supplementary Figure 4D and 183 
Supplementary Table 3). 184 
Outcome modeling of combined clinical and PDE4D7 score categories  185 
The data presented here indicate that the risk of disease progression provided by 186 
PDE4D7 scores offers a novel insight into prostate cancer risk assessment and thus is 187 
set to be complementary to the risks provided by clinical practice criteria. Thus, we 188 
hypothesized that the combination with clinical risk scores by computational modeling 189 
might predict long-term disease outcomes more effectively compared to using any single 190 
score alone. To evaluate this hypothesis we selected a sub-cohort of 449 patients (92 191 
events; 20.5%) with complete 5-year outcome histories and generated a logistic 192 
regression model to combine the established clinical metric of the CAPRA-S score 193 
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categories with the PDE4D7 score in order to predict the 5-year risk of biochemical 194 
recurrence after surgery. The modeling proved the independent predictive value of the 195 
PDE4D7 scores (Odds ratio 0.45; 95% CI 0.29-0.67; p=0.0001; data not shown). ROC 196 
analysis calculated the 2-, 5-year AUCs as 0.82, and 0.78, respectively. The PDE4D7 197 
score showed incremental value to the AUC of CAPRA-S categories alone of 6% 198 
(p=0.0004) and 4% (p=0.003) to the 2-year and 5-year post-surgical progression 199 
prediction, respectively (Figures 2A and 2B). Cross-validation of the logistic regression 200 
model in the validation cohort showed AUC’s of 0.77 and 0.74 for the 2-year and 5-year 201 
outcome prediction respectively. The logit function of the regression model was used to 202 
predict the individual 5-year BCR PFS. Predicted risk analysis per clinical risk group as a 203 
function of PDE4D7 scores revealed heterogeneous 5-year progression risk distribution 204 
even within the lowest CAPRA-S risk category (Figure 3).   205 
To evaluate this further we modeled the probability of biochemical recurrence in 206 
the study cohort after surgery by Cox regression using the CAPRA-S risk categories as 207 
well as the continuous PDE4D7 score as inputs. The regression function was used to 208 
calculate the probability of biochemical progression after surgery for the patient study 209 
cohort. Based on the progression probability we defined four risk groups of PSA failure 210 
and compared this to survival prediction of the CAPRA-S score categories alone 211 
(Figures 4A & 4B). When using probability group (0 to <0.1) as a reference in the 212 
Kaplan-Meier analysis the hazard ratio’s for probability groups (0.1 to <0.25), (0.25 to 213 
<0.5), and (0.5 to 1.0) were 2.0 (95% CI 1.4-2.9), 5.7 (95% CI 3.5-9.1), and 17.2 (95% 214 
CI 6.0-49.2) compared to hazard ratio’s of 2.9 (95% CI 2.0-4.1) and 8.4 (95% CI 3.9-215 
17.8) for the CARPA-S score category model (Supplementary Tables 6 & 7).  We tested 216 
the CAPRA-S & PDE4D7 Cox regression model in the validation cohort to confirm that 217 
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the four probability groups represents patient cohorts with significant difference in post-218 
surgical risk of disease progression (Figure 4C; Supplementary Table 8). We finally 219 
applied Kaplan Meier survival analysis to demonstrate the ability of PDE4D7 to re-220 
stratify the risk in particular the CAPRA-S (2) and (3) patients into groups of patients with 221 
high BCR PFS (>70%) vs. those with low BCR PFS (<20%) (Supplementary Table 10). 222 
We have illustrated that the measurement of the prostate cancer biomarker 223 
PDE4D7 in a tumor sample provides risk stratification information to predict long-term 224 
clinical outcomes. Moreover, PDE4D7 provided independent and incremental value to 225 
the existing risk prediction algorithm CAPRA-S.  226 
227 
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Discussion  228 
The management of prostate cancer patients is strongly dependent on risk profiling. 229 
Several risk metrics based on clinical inputs have been developed to predict either 230 
before or after surgery the risk of PSA progression.2 Cooperberg and colleagues 231 
presented the  post-surgical prediction algorithm CAPRA-S which is based on a 232 
weighted sum of scores for the clinical variables pre-operative PSA, pathology Gleason 233 
score, pathology status of extracapsular extension, seminal vesicle invasion, surgical 234 
margins and lymph node invasion11. The resulting CAPRA-S score is categorized into 235 
three groups representing low (CAPRA-S 0-2), intermediate (CARPA-S 3-5), and high 236 
(CAPRA-S ≥6) risk of disease progression after surgery. The c-index was inititally 237 
reported to be 0.77 for 5-year BCR progression free survival (Cooperberg et al). In a 238 
large validation study using external data a c-index of 0.73 for prediction of BCR at 5 239 
years after surgery was published.15 The CAPRA-S score is one of the most extensively 240 
validated clinical risk metric.  241 
Alterations in the expression of members of the cAMP-degrading PDE4 family are 242 
associated with several diseases, including stroke,16 acrodysostosis,17,18 243 
schizophrenia,19 and COPD20. Functionally, PDE4D it provides part of the cellular 244 
desensitization system to cAMP and enables cross-talk between signaling pathways that 245 
lead to the activation of ERK and AMPK21, for example. Recently, we have shown that 246 
down-regulation a particular PDE4 isoform (PDE4D7) may impact on prostate 247 
cancer13,22,23.   248 
 249 
 250 
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Therefore, we investigated the incremental value of PDE4D7 to CAPRA-S to predict 251 
post-surgical PSA relapse.  252 
To test this we generated logistic and Cox regression models for BCR 253 
progression free survival (BCR PFS) to combine the CAPRA-S categorical score with 254 
the continuous PDE4D7 score. Both regression models showed better performance in 255 
predicting fast relapse within 24 months after the primary treatment. The incremental 256 
value of PDE4D7 to the CARPA-S was larger in this setting compared to the 5-year 257 
outcome prediction (6% vs. 4%, respectively); however, in both settings the incremental 258 
contribution of the PDE4D7 score was statistically significant.  259 
Testing the PDE4D7 score in Cox regression modeling with CAPRA-S to model 260 
time to PSA recurrence indicated the impact of PDE4D7 for patients at high risk of post-261 
surgical PSA relapse within 24-36 months after operation. The Kaplan Meier analysis 262 
showed that patients with the highest probability of relapse after surgery had a mean 263 
progression free survival of 44.6 months when stratified with the CAPRA-S & PDE4D7 264 
combined score vs. 64.3 months for the CARPA-S model alone.  265 
Not all patients with PSA failure after local therapy have the same prognostic 266 
pathway in terms of future disease progression. Fast PSA doubling times and fast PSA 267 
recurrence after surgery have been significantly associated with progression to 268 
metastases and prostate cancer specific mortality.24 In our study cohort we confirmed 269 
the correlation between the mean time to BCR and prostate cancer specific death. The 270 
mean BCR PFS of 44.6 months in the highest CAPRA-S & PDE4D7 risk group 271 
corresponds to a 22.2% risk of prostate cancer specific in this cohort. In contrast to a 272 
risk of 11.9% to die from prostate cancer in the the CAPRA-S category (3) patient group 273 
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with mean 64.3 months BCR PFS. These data support the view that lowest level of 274 
PDE4D7 scores contribute to higher risk of rapid recurrence after primary intervention. 275 
Several retrospective studies have provided evidence that stratification of patients to 276 
salvage radiation therapy after local failure based on time to PSA recurrence may 277 
increase cancer specific survival.25,26 Thus, accurate stratification of patients is essential 278 
to provide most optimal therapeutic strategies for patients.     279 
Our study is limited by the retrospective design. Due to the long-term follow-up of 280 
10-15 years as well as the chosen design to investigate a consecutively managed 281 
patient cohort the clinical risk distribution may not completely represent the risk of a 282 
contemporary surgery cohort. The study population includes a limited number high-risk 283 
cases which may limit the generalizability of our presented results to high-risk 284 
populations. This is important to note as one of our main findings is that PDE4D7might 285 
support improved stratification of patients at high risk of post-surgical disease 286 
recurrence. Thus, PDE4D7 may have a role in the selection of secondary treatments for 287 
this patient group. However, to confirm this further research in clinically high-risk patient 288 
cohorts is required. 289 
  290 
Conclusions  291 
We have validated the prostate cancer biomarker PDE4D7 in a historic patient cohort 292 
consecutively managed by radical prostatectomy. We confirmed the independent 293 
prognostic and incremental value of PDE4D7 score next to the established clinical risk 294 
metric CAPRA-S score. The PDE4D7 score may support the risk stratification of patients 295 
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after local treatment to select the right timing for start of secondary therapy for men at 296 
very high risk of rapid disease recurrence.  297 
  298 
17 
 
4) References 299 
1. Ferlay J, Soerjomataram I, Ervik M: GLOBOCAN 2012 v1.0, Cancer Incidence and 300 
Mortality Worldwide: IARC CancerBase. No. 11 [Internet]. Lyon. Fr. Int. Agency Res. 301 
Cancer 11: http://globocan.iarc.fr, 2013 302 
2. Lughezzani G, Briganti A, Karakiewicz PI et al: Predictive and Prognostic Models in 303 
Radical Prostatectomy Candidates: A Ciritical Analysis of the Literature. EUr Urol 58: 304 
687-700, 2010 305 
3. Hernandez DJ, Nielsen ME, Han M, Partin AW: Contemporary evaluation of the 306 
D'amico risk classification of prostate cancer. J Urology 70 (5): 931-5, 2007 307 
4. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML: Mayo Clinic validation of 308 
the D'amico risk group classification for predicting survival following radical 309 
prostatectomy. J Urol 179 (4): 1354-60, 2008  310 
5. Reese AC, Pierorazio PM, Han M, Partin AW: Contemporary evaluation of the 311 
National Comprehensive Cancer Network prostate cancer risk classification system. 312 
Urology 80 (5): 1075-9, 2012 313 
6. Boström PJ, Bjartell AS, Catto JWF et al: Genomic Predictors of Outcome in Prostate 314 
Cancer. Eur Urol 68: 1033-1044, 2015 315 
7. Merkle D, Hoffmann R: Roles of cAMP and cAMP-dependent protein kinase in the 316 
progression of prostate cancer: Cross-talk with the androgen receptor. Cellular 317 
Signalling 507-515, 2011 318 
8. Conti M, Beavo J: Biochemistry and physiology of cyclic nucleotide 319 
phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev 320 
Biochem 76: 481-511, 2007 321 
18 
 
9. Lugnier, C: Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for 322 
the development of specific therapeutic agents. Pharmacology and Therapeutics 366–323 
398, 2006 324 
10. Houslay, MD: Underpinning compartmentalised cAMP signalling through targeted 325 
cAMP breakdown. Trends in Biochemical Sciences 91–100, 2010 326 
11. Cooperberg MR, Hilton JF, Caroll, PR: The CAPRA-S score: a straight-forward tool 327 
for improved prediction of outcomes afte radical prostatectomy. Cancer 117 (22): 5039-328 
5046, 2011 329 
12. Taylor BS, Schultz N, Hieronymus H, et al: Integrative Genomic Profiling of Human 330 
Prostate Cancer. Cancer Cell 18: 11-22, 2010 331 
13. Böttcher R, Henderson DJP, Dulla K et al: Human phosphodiesterase 4D7 332 
(PDE4D7) expression is increased in TMPRSS2-ERG positive primary prostate cancer 333 
and independently adds to a reduced risk of post-surgical disease progression. Br J 334 
Cancer 113: 1502-1511, 2015 335 
14. Purdom E, Simplson KM, Robinson MD, et al: FIRMA: a method for detection fo 336 
alternative splicing from exon array data. Bioinformatics 24(15): 1707-1714, 2008 337 
15. Punnen S, Freedland SJ, Presto Jr JC, et al: Multi-institutional Validation of the 338 
CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical 339 
Prostatectomy. Eur Urol 65: 1171-1177, 2014 340 
16. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, et al: The gene encoding 341 
phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 35(2): 131–138, 2003 342 
17. Michot C, Le Goff C, Goldenberg A, et al: Exome sequencing identifies PDE4D 343 
mutations as another cause of acrodysostosis. Am J Hum Genet 90(4): 740–745, 2012 344 
19 
 
18. Lee H, Graham JM, Rimoin DL, et al: Exome sequencing identifies PDE4D 345 
mutations in acrodysostosis." Am J Hum Genet 90(4): 746–751, 2012 346 
19. Tomppo L, Hennah W, Lahermo P, et al: Association Between Genes of Disrupted in 347 
Schizophrenia 1 (DISC1) Interactors anSchizophrenia Supports the Role of the DISC1 348 
Pathway in the Etiology of Major Mental Illnesses . Biol Psychiatry 65(12): 1055–1062, 349 
2009 350 
20. Yoon H-K, Hu H-J, Rhee C-K, et al: Polymorphisms in PDE4D are associated with a 351 
risk of COPD in non-emphysematous Koreans. COPD 11(6): 652–658, 2014 352 
21. Baillie GS, Sood A, McPhee I, et al: beta-Arrestin-mediated PDE4 cAMP 353 
phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. 354 
Proc Natl Acad Sci 100(3): 940-945, 2003 355 
22. Henderson DJP, Byrne A, Dulla K et al: The cAMP phosphodiesterase-4D7 356 
(PDE4D7) is downregulated in androgen-independent prostate cancer cells and 357 
mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP 358 
prostate cancer cells. Br J Cancer 110: 1278-1287, 2014 359 
23. Böttcher R, Dulla K, Strijp D van et al: Human PDE4D isoform composition is 360 
deregulated in primary prostate cancer and indicative for disease progression and 361 
development of distant metastases. Oncotarget, 2016; 7:70669-70684 362 
24. Paller CJ, Antonarakis ES: Management of Biochemically Recurrent Prostate 363 
Cancer After Local Therapy: Evolving Standards of Care and New Directions. Clin Adv 364 
Hemtail Oncol 11(1): 14-23, 2013 365 
25. Cotter SE, Chen MH, Moul JW, et al: Salvage radiation in men after prostate-specific 366 
antigen failure and the risk of death. Cancer, 117: 3925-3932, 2011 367 
20 
 
26. Trock BJ, Han M, Freedland SJ, et al: Prostate cancer-specific survival following 368 
salvage radiotherapy vs observation in men with biochemical recurrence after radical 369 
prostatectomy. JAMA, 299: 2760-2769, 2008  370 
21 
 
5) Figures and Tables 371 
Table 1: Patient demographics of the analyzed patient surgery study cohort 372 
  Parameter Study cohort (n=503) Validation cohort (n=130) 
Demographic & 
Clinical -  
Range (median; IQR) 
Age range 41.3-74.5 (62.6; 7.4) 37.3-83 (58.0; 8.7) 
Preoperative PSA range 0.18-73.16 (6.7; 5.5) 1,15-46.4 (5.9; 4.6) 
Percent tumor in biopsy 
range 
0.2-79.7 (10.3; 16.0) N/A 
Prostate Volume range 9-148 (42; 22.5) N/A 
PSA density range 0.18-73.2 (6.7; 5.5) N/A 
NCCN Risk Category -  
Number of patients 
(percentage) 
Very Low Risk 67 (13.3%) 
58 (44.6%) 
Low Risk 144 (28.6%) 
Intermediate Favorable 
Risk 
128 (25.4%) 32 (24.6%) 
Intermediate unfavorable 
Risk 
120 (23.9%) 21 (16.2%) 
High Risk 44 (8.7%) 19 (14.6%) 
Pre-Surgery Pathology 
-  
Number of patients 
(percentage) 
Biopsy Gleason 3+3 316 (62.8%) 78 (60.0%) 
Biopsy Gleason 3+4 149 (29.6%) 29 (22.3%) 
Biopsy Gleason 4+3 25 (5.0%) 12 (9.2%) 
Biopsy Gleason >=4+4 13 (2.6%) 11 (8.5%) 
cT1 342 (68%) 74 (56.9%) 
cT2 150 (29.8%) 51 (39.2%) 
cT3 11 (2.2%) 5 (3.8%) 
Post-Surgery 
Pathology -  
Number of patients 
(percentage) 
Pathology Gleason 3+3 201 (40%) 42 (32.3%) 
Pathology Gleason 3+4 257 (51.1%) 53 (40.8%) 
Pathology Gleason 4+3 41 (8.2%) 21 (16.2%) 
Pathology Gleason >=4+4 4 (0.8%) 14 (10.8%) 
pT2 331 (65.8%) 85 (65.4%) 
pT3 172 (34.2%) 39 (30.0%) 
pT4 0 (0%) 6 (4.6%) 
Positive Surgical Margins 120 (23.9%) 29 (22.3%) 
Extracapsular Extension 
(=T3a) 
113 (22.5%) 87 (66.9%) 
Seminal Vesicle Invasion 60 (11.9%) 13 (10.0%) 
Lymph Node Invasion 5 (1%) 5 (3.7%) 
Follow-up [months] 
(IQR follow-up) 
Mean 123.6 58.2 
Median 141.8 (60.1) 54.2 (35.6) 
Outcome - Number 
events/total patient 
number (percentage; 
follow-up; IQR) 
BCR within 5 years 92/446 (20.6%; 121.2; 87.5) 26/130 (20.0%; 46.9; 33.6) 
BCR within 10 years 134/347 (38.6%; 134.0; 95.6)    
CR within 5 years 5/441 (1.1%; 144.4; 37.8) 8/130 (6.2%; 52.3; 34.9) 
CR within 10 years 13/306 (4.2%; 154.7; 32.85)   
Salvage Treatment - 
Number events/total 
patient number 
(percentage; follow-up; 
IQR) 
SRT within 5 years 53/439 (12.1%; 120.4; 53.5) 13/130 (10.0%; N/A;N/A) 
SRT within 10 years 83/320 (25.9%; 132.3; 39.6)   
SADT within 5 years 27/441 (6.1%; 120.7; 46.6) 14/130 (10.8%; N/A; N/A) 
SADT within 10 years 54/312 (17.3%; 132.4; 24.2)   
Survival - Number 
events/total patient 
number (percentage; 
follow-up; IQR) 
PCSM within 5 years 17/453 (1.1%; 144.4; 37.7) 0/130 (0%; N/A; N/A) 
PCSM within 10 years 38/330 (2.6%; 154.8; 30.3)   
OM within 5 years 5/441 (3.7%; 144.4; 45.1) N/A 
OM within 10 years 10/302 (11.2%; 146.0; 35.4)   
 373 
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Table 2A: Uni- and multivariate Cox regression analysis of the biochemical recurrence 374 
(BCR) free survival of the PDE4D7 score in the patient surgery cohort adjusted for post-375 
surgical clinical variables in the study cohort (n=503) 376 
 377 
Post-Surgical Clinical Parameters univariate multivariate 
Endpoint BCR (#503/#148; 29.4%) p-value HR 
95% CI of 
HR 
p-value HR 
95% CI of 
HR 
Pathology Gleason score 3+3 (n=201); reference  
Pathology Gleason score 3+4 
(n=257) 
0.003 2.10 1.4-3.1 0.24 0.77 0.5-1.2 
Pathology Gleason score 4+3 (n=41) <0.0001 8.60 5.2-14.2 <0.0001 2.6 1.7-4.2 
Pathology Gleason score ≥4+4 (n=4) <0.0001 27.7 9.7-79.2 <0.0001 13.3 4.5-39.4 
 
Pathology Stage pT2 (n=331); reference  
Pathology Stage pT3 (n=172) <0.0001 4.30 3.1-6.0 0.0001 2.4 1.6-3.6 
 
Surgical Margin Status (SMS) <0.0001 2.60 1.8-3.6 0.0006 1.0 1.3-2.7 
Seminal Vesicle Invasion (SVI) <0.0001 4.50 3.1-6.4 0.027 1.6 1.1-2.5 
Lymph Node Invasion (LNI) <0.0001 55.7 
20.9-
148.6 
0.0015 5.5 1.9-15.6 
PDE4D7 Score (continuous) <0.0001 0.53 0.41-0.67 <0.0001 0.56 0.43-0.73 
 378 
 379 
  380 
23 
 
Table 2B: Uni- and multivariate Cox regression analysis of the biochemical recurrence 381 
(BCR) free survival of the PDE4D7 score in the patient surgery cohort adjusted for the 382 
CAPRA-S score in the study cohort (n=503) 383 
 384 
Post-Surgical 
Clinical Parameters 
univariate (enter) multivariate (enter) 
Endpoint BCR 
(#503/#148; 29.4%) 
p value HR 
95% CI of 
HR 
p value HR 
95% CI of 
HR 
CAPRA-S score category (1) (n=288); reference 
CAPRA-S score 
category (2) (n=173) 
<0.0001 2.9 2.0-4.2 <0.0001 2.9 2.04.2 
CAPRA-S score 
category (3) (n=42) 
<0.0001 8.7 5.5-13.7 <0.0001 8.4 5.3-13.3 
PDE4D7 
(continuous) 
<0.0001 
0.5
3 
0.41-0.67 <0.0001 0.54 0.42-0.69 
  385 
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Table 2C: Uni- and multivariate Cox regression analysis of the biochemical recurrence 386 
(BCR) free survival of the PDE4D7 score in the patient surgery cohort adjusted for the 387 
CAPRA-S score in the study cohort (n=503) 388 
 389 
Post-Surgical 
Clinical Parameters 
univariate (enter) multivariate (enter) 
Endpoint BCR 
(#503/#148; 29.4%) 
p value HR 
95% CI of 
HR 
p value HR 
95% CI of 
HR 
CAPRA-S score category (1) (n=288); reference 
CAPRA-S score 
category (2) (n=173) 
<0.0001 2.9 2.0-4.2 <0.0001 2.9 2.04.2 
CAPRA-S score 
category (3) (n=42) 
<0.0001 8.7 5.5-13.7 <0.0001 8.2 5.2-13.1 
PDE4D7 score (4-5) (n=85); reference 
PDE4D7 score (3-4) 
(n=289) 
0.02 2.1 1.1-3.8 0.02 2.1 1.2-3.9 
PDE4D7 score (2-3) 
(n=118) 
<0.0001 3.8 2.0-7.1 0.0001 3.5 1.8-6.5 
PDE4D7 score (1-2) 
(n=1) 
0.0005 5.7 2.1-15.2 0.0007 5.5 2.1-14.7 
  390 
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Figure 1A Regression terms for the PDE4D7 scores calculated from Cox proportional 391 
hazard model predicting biochemical recurrence (BCR) free survival in the study cohort 392 
(n=503) 393 
 394 
 395 
 396 
  397 
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Figure 1B: Kaplan-Meier analysis of the PDE4D7 score with biochemical recurrence 398 
(BCR) free survival in the study cohort (n=503) 399 
 400 
 401 
 402 
 403 
 404 
 405 
  406 
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Figure 1C: Kaplan-Meier analysis of the PDE4D7 score with biochemical recurrence 407 
(BCR) free survival in the in the validation cohort (n=130)  408 
 409 
 410 
  411 
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Figure 2A: ROC cure analysis of 2-year biochemical recurrence (BCR) for the 412 
incremental value of the PDE4D7 score added to the CAPRA-S score categories by 413 
logistic regression analysis in the study cohort (n=469) 414 
 415 
  416 
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Figure 2B: ROC cure analysis of 5-year biochemical recurrence (BCR) for the 417 
incremental value of the PDE4D7 score added to the CAPRA-S score categories by 418 
logistic regression analysis in the study cohort (n=449) 419 
 420 
  421 
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Figure 3: Analysis of 5-year biochemical (BCR) recurrence free survival predicted by a 422 
logistic regression model of the CAPRA categories and the PDE4D7 scores in a patient 423 
sub-cohort with complete 5-year follow-up in the study cohort (n=449) 424 
 425 
 426 
 427 
 428 
 429 
 430 
 431 
  432 
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Figure 4A: Kaplan-Meier analysis of the biochemical recurrence (BCR) free survival 433 
predicted by the CAPRA-S score categories in the study cohort (n=503) 434 
 435 
  436 
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Figure 4B: Kaplan-Meier analysis of the biochemical recurrence (BCR) free survival 437 
predicted by a Cox regression model of the CAPRA-S categories and the PDE4D7 score 438 
in the study cohort (n=503) 439 
 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
 449 
 450 
 451 
 452 
 453 
 454 
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Figure 4C: Kaplan-Meier analysis of the biochemical recurrence (BCR) free survival 455 
predicted by a Cox regression model of the CAPRA-S categories and the PDE4D7 score 456 
in the validation cohort (n=130) 457 
 458 
 459 
 460 
 461 
 462 
 463 
 464 
 465 
 466 
 467 
 468 
 469 
 470 
 471 
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Figure and Table Legends 472 
Table 1 – Demographics of the patient study cohort including the 503 patients eligible 473 
for statistical data analysis: patients were operated between the years 2000-2004. For 474 
patient age, preoperative PSA, percentage of tumor in biopsy, prostate volume and PSA 475 
density the min and max values in the cohort are shown; median and IQR are depicted 476 
in parentheses. For the NCCN Risk categories the number of patient per risk group and 477 
percentage of the total cohort are shown. In case of pre-surgical pathology the biopsy 478 
Gleason grade groups as well as clinical stages are indicated (total number; percentage 479 
of patients). Post-surgical pathology is represented by the pathology Gleason grade 480 
groups, the pathology stages, the surgical margin status after prostatectomy, the tumor 481 
invasion status of the seminal vesicles and pelvic lymph nodes (number; percentage of 482 
patients). Note: extracapsular extension was not provided as a primary parameter but 483 
was derived from pathology stage pT3a. The follow-up demonstrates the mean and 484 
median follow up periods in months after surgery for all patients. The outcome category 485 
illustrates the cumulative 5- and 10-year biochemical recurrence (BCR) and clinical 486 
recurrence to metastases (CR) post-surgical primary treatment. The treatment category 487 
lists the cumulative 5- and 10-year start to SRT (salvage radiation therapy) or SADT 488 
(salvage androgen deprivation therapy) after surgery. Mortality is shown as prostate 489 
cancer specific mortality (PCSM) as well as overall mortality (OM). For all outcomes, the 490 
number of men experiencing the outcome per total number of men with the respective 5- 491 
or 10-year follow are shown; percentage of events, median follow-up in that group as 492 
well as IQR are given in parentheses. Demographics of the 130 patient validation cohort: 493 
resected prostate tissues of in total 218 patients were profiled by several molecular 494 
biology techniques as described earlier (Taylor et al: Integrative genomic profiling of 495 
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human prostate cancer. Cancer Cell 18(1):11-22, 2011). We excluded for our validation 496 
analysis all samples corresponding to either histologically normal prostate tissue, 497 
metastases or castration resistant disease. Further, patients were selected for 498 
availability of exon microarray data to derive PDE4D7 transcript expression. In addition, 499 
only patients with a primary tumor and information on biochemical recurrence (BCR) and 500 
clinical recurrence to metastases (CR) were included into the validation data analysis. 501 
The characteristics of the 130 eligible patients are summarized as published and is 502 
shown equivalent to the study cohort. The available outcomes are presented as number 503 
of events during the available follow-up period. Percentage of events, median follow-up 504 
and IQR are presented where available in parentheses. 505 
Table 2 – (A) Uni- and multivariate Cox regression analysis of the biochemical 506 
recurrence (BCR) free survival of the continuous and categorical PDE4D7 scores in the 507 
study cohort (n=503); in the multi-variate analysis the PDE4D7 Scores were adjusted by 508 
post-surgical clinical variables as indicated. Pathology Gleason and pathology stage 509 
were modeled as categories with the lowest category used as a reference; the status on 510 
surgical margins, seminal vesicle and lymph node invasion were modeled as continuous 511 
variables. Note: pre-operative PSA did not add independent value in the multi-variate 512 
analysis and was therefore not included. (B) Uni- and multivariate Cox regression 513 
analysis of the biochemical recurrence (BCR) free survival of the PDE4D7 score 514 
adjusted for the CAPRA-S score categories in the in the study cohort (n=503); PDE4D7 515 
was modeled as continuous variable. (C) Uni- and multivariate Cox regression analysis 516 
of the biochemical recurrence (BCR) free survival of the PDE4D7 score in the patient 517 
study cohort adjusted for the CAPRA-S score categories (n=503); PDE4D7 was 518 
modeled as categorical variable. The number of patients in each reference and 519 
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categorical group, the Hazard Ratio’s (HR), 95% confidence intervals (CI) and p-values 520 
are provided. The CAPRA-S score category is defined as: CAPRA-S (1): CAPRA-S 521 
scores 0-2; CAPRA-S (2): CAPRA-S scores 3-5; CAPRA-S (3): CAPRA-S scores ≥6. 522 
PDE4D7 score categories are defined as: PDE4D7 (1-2): PDE4D7 scores (1 to <2); 523 
PDE4D7 (2-3): PDE4D7 scores (2 to <3); PDE4D7 (3-4): PDE4D7 scores (3 to <4); 524 
PDE4D7 (4-5): PDE4D7 scores (4 to <=5).  525 
Figure 1 – (A) Regression terms for the continuous PDE4D7 scores were calculated 526 
from the Cox proportional hazard model predicting BCR (biochemical recurrence) 527 
progression free survival (n=503). Regression term plots were calculated using the 528 
termplot function of the survival package in R. For the PDE4D7 scores a pspline basis 529 
was used to calculate a smoothed line using the pspline function. The Hazard ratio is 530 
indicated as a function of the PDE4D7 scores. The dashed lines represent the standard 531 
error. Tick marks at bottom indicate the number and distribution of patients. (B) Kaplan 532 
Meier analysis of the time to PSA relapse after prostatectomy of the PDE4D7 score 533 
categories in the study cohort (n=503; logrank p<1.0E-04). (C) Kaplan Meier analysis of 534 
the time to biochemical recurrence of the PDE4D7 score categories in the validation 535 
cohort (n=130; logrank p=0.03). Censored patients are indicated by vertical bars. 536 
Number of men at risk are given in the table below the Kaplan Meier survival graph. 537 
PDE4D7 score categories are defined as: PDE4D7 (1-2): PDE4D7 scores (1 to <2); 538 
PDE4D7 (2-3): PDE4D7 scores (2 to <3); PDE4D7 (3-4): PDE4D7 scores (3 to <4); 539 
PDE4D7 (4-5): PDE4D7 scores (4 to <=5). The highest PDE4D7 score category (4-5) 540 
was used as the reference category. 541 
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Figure 2 – (A) ROC cure analysis of 2-year biochemical recurrence (BCR) for the 542 
incremental value of the PDE4D7 score added to the CAPRA-S score categories by 543 
logistic regression analysis in the study cohort (n=469). (B) ROC cure analysis of 5-year 544 
biochemical recurrence (BCR) for the incremental value of the PDE4D7 score added to 545 
the CAPRA-S score categories by logistic regression analysis in the study cohort 546 
(n=449). The PDE4D7 score was modeled as a continuous variable in the logistic 547 
regression. For the prediction of the 2-year PSA relapse after surgery the incremental 548 
value of PDE4D7 as 0.06 yielding an AUC of 0.82 in comparison of 0.76 for the CAPRA-549 
S score category model alone (p=0.0004). In case of the 5-year biochemical recurrence 550 
prediction after radical prostatectomy the incremental addition of PDE4D7 was 0.04; the 551 
AUC of the logistic regression model was calculated to 0.78 while the for the CAPRA-S 552 
score category model alone the AUC was 0.74 (p=0.003). 553 
Figure 3 – 5-year risk of biochemical recurrence (BCR) free survival predicted by a 554 
logistic regression model of the CAPRA-S score categories and the PDE4D7 scores in a 555 
sub-cohort of the study population with complete 5-year follow-up (n=449). The CAPRA-556 
S score categories were modeled by logistic regression with the continuous PDE4D7 557 
scores. The logit(p) function was transformed to p=1/(1+e^(-logit(p)) in order to calculate 558 
the probability p for an individual patient to experience a biochemical relapse within 5 559 
years after surgery. The 5-year predicted probability p is plotted against the PDE4D7 560 
score category for each individual CAPRA score category as illustrated. The CAPRA-S 561 
score category is defined as: CAPRA-S (1): CAPRA-S scores 0-2; CAPRA-S (2): 562 
CAPRA-S scores 3-5; CAPRA-S (3): CAPRA-S scores ≥6. PDE4D7 score categories 563 
are defined as: PDE4D7 (1-2): PDE4D7 scores (1 to <2); PDE4D7 (2-3): PDE4D7 564 
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scores (2 to <3); PDE4D7 (3-4): PDE4D7 scores (3 to <4); PDE4D7 (4-5): PDE4D7 565 
scores (4 to ≤5). 566 
Figure 4 – (A) Kaplan-Meier analysis of the biochemical recurrence (BCR) free survival 567 
predicted by the CAPRA-S score categories in the study patient cohort in the study 568 
cohort (n=503). (B) 5-year probability of biochemical recurrence (BCR) free survival 569 
predicted by a Cox regression model of the CAPRA-S score categories and the PDE4D7 570 
scores in the study population (n=503) analyzed by Kaplan Meier. The CAPRA-S score 571 
categories were modeled in combination with the continuous PDE4D7 scores. The 572 
CAPRA-S&PDE4D7 Cox regression function was transformed to a progression 573 
probability p=(HR/(1+HR)). Four patient categories were defined based on the predicted 574 
5-year probability p to experience biochemical recurrence: group 1 (probability 0 to <0.1; 575 
n=119); group 2 (probability 0.1 to <0.25; n=238); group 3 (probability 0.25 to <0.5; 576 
n=119); group 4 (probability 0.5 to 1.0; n=27). (C) Testing the Cox regression model in 577 
the independent validation patient cohort (n=130). The patient categories were defined 578 
in the same way as above based on the CAPRA-S&PDE4D7 Cox regression model 579 
developed on the study cohort. Censored patients are indicated by vertical bars. Number 580 
of men at risk are given in the table below the Kaplan Meier survival graph. plotted 581 
against the PDE4D7 score category for each individual CAPRA score category as 582 
illustrated. The CAPRA-S score category is defined as: CAPRA-S (1): CAPRA-S scores 583 
0-2; CAPRA-S (2): CAPRA-S scores 3-5; CAPRA-S (3): CAPRA-S scores ≥6. PDE4D7 584 
score categories are defined as: PDE4D7 (1-2): PDE4D7 scores (1 to <2); PDE4D7 (2-585 
3): PDE4D7 scores (2 to <3); PDE4D7 (3-4): PDE4D7 scores (3 to <4); PDE4D7 (4-5): 586 
PDE4D7 scores (4 to <=5). 587 
